CIC and U 1116


Faiez Zannad
Professor of Therapeutics and Cardiology, Head of CIC

Hôpital Brabois
Bâtiment Louis mathieu
54500 Vandoeuvre-Les-Nancy

Tel : +33 3 83 15 73 22
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.

Faiez Zannad is Professor of Therapeutics and Cardiology. He is at the Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU) of Nancy since 1995.

He entered the European Society of Cardiology (ESC) in 1996 and is currently the Chairman of the ESC Working group on Pharmacology and Drug Therapy as well as a Boardmember of the ESC Heart Failure Association. He is Past-President of the French Society of Hypertension. As the Coordinator of French Cardiovascular Clinical Investigation Centres, he has participated in various famous large scale trials in human cardiology such as RALES,VALIANT, CIBIS, CAPRICORN, EPHESUS or EMPHASIS-HF. In these trials, he has been involved either as a member of the Steering Committees or in the Protocol Writing Groups.
He is Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.



Frederic Jaisser
MD, PhD, Director of INSERM Unit U1138

Cordeliers Research Center
15, rue de l'Ecole de Medecine
75270 Paris Cedex 06


Tel : +33 1 44 27 81 06
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.


Frederic JAISSER, MD, PhD got a permanent position as Director of Research at the National Institute of Health and Medical Research (INSERM) in 1996. Dr. JAISSER received his medical training and degrees from the Reims Medical School and was qualified as Nephrologist in 1990. In 2003, he joined the Collège de France in Paris as an independent INSERM team and is currently the director of a team of the INSERM Unit U1138, at the Cordeliers Research Centre, Paris. He is the head of the "Integrative Physiology and Pathophysiology " Department of the Cordeliers Research Centre". Since 2010, he is Scientific Delegate of the Pathophysiology Committee of the French National Research Agency.

The aim of his current studies is to improve the understanding of the pathophysiological roles and signaling pathways whereby the hormone aldosterone promotes pathologies in various organs including the kidney and the cardiovascular system. His work combines cellular and molecular approaches, animal physiology, pharmacological studies and has implications in human diseases. His interest includes translational research aimed to identify and validate biomarkers of Mineralocorticoid Receptor activation in cardiovascular and kidney diseases and novel therapeutic use of MR antagonists. Dr JAISSER belongs to several research networks, including EU-granted programs. More recently he was appointed as Coordinator of a European Network on Aldosterone with more than 45 laboratories from 15 EU countries dedicated to the Aldosterone field, covering the continuum from experimental to clinical studies
( ).

Favorite papers
Zhao M, I. Celerier, E. Bousquet, J-C Jeanny, L.Jonet, M. Savoldelli, O. Offret, A. Curan, N.Farman*, F.Jaisser*, F. Behar-Cohen*. Mineralocorticoid receptor activation leads to ocular choroidal vessel dilation in rats and human central serous chorioretinopathy. Journal of Clinical Investigation. 2012 * equally contributed
Ouvrard-Pascaud, Y. Sainte-Marie, J.P. Bénitah, R. Perrier, A. Nguyen, A. Royer, K. Le Quang, F.Charpentier, S.Demolombe, F. Mechta-Grigoriou, A. Beggah, P. Maison-Blanche, M.-E. Oblin, C.Delcayre, G. Fishman, N. Farman, B. Escoubet, F. Jaisser Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005 ;111(23):3025-33.

Journal to publish the review : J endocrinology



Thiên-Ly Pham
Project Manager

Inserm Transfert
Paris Biopark
7 rue de watt
75103 Paris

Tel : +33 (0)1 55 03 01 35
Fax : +33 (0)1 55 03 01 60
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.

Thiên‐Ly Pham has a Diplôme d’Ingénieur (five year degree) from Ecole Centrale de Lille, a top French general engineering school. She specialized in biomedical engineering with an MSc in Medical Diagnostics degree in England, and a PhD in medical imaging in France. She worked at LNE/G‐Med as a Certification Project Manager for in vitro diagnostic medical devices. She went into the field of international cooperation in research and higher education and worked as a scientific officer at the French Embassy in Sweden for two years, then as a European affairs officer at Inserm. She managed the subproject “Cognitive architectures” within the Human Brain Project, a European Commission Future and Emerging Technologies Flagship for 3 years at CEA (French Alternative Energies and Atomic Energy Commission). She joined Inserm Transfert in 2016 and is currently managing two FP7 projects and an H2020 project.




Javier Díez, MD, PhD
Director of Research

Avd. Pío XII, 55 | E-31008

Tel : +34 948 194 700
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.  

Full Professor of Cardiovascular Medicine, School of Medicine, University of Navarra
Director, Division of Cardiovascular Sciences, Centre for Applied Medical Research
Consultant and Chief, Area of Molecular Cardiology, Department of Cardiology and Cardiovascular Surgery, University Clinic.
Pamplona, Spain

Dr. Díez graduated in Medicine at the Medical School of the Autónoma University of Madrid, in 1976, and holds a certificate of Nephrology and Internal Medicine at the University Clinic of the University of Navarra, in Pamplona, in 1982. He next became a research fellow at the Necker Hospital, Paris, from 1982 to 1984, and at the Brigham and Women's Hospital, Boston, in 1985, where he trained in cardiovascular biology. On his return to Spain he served as Professor of Medicine at the University of Zaragoza before returning to the University of Navarra where he obtained a tenured position at the University Clinic and soon became head of a research unit at the School of Medicine. In 2002 he was appointed as Professor of Vascular Medicine at the School of Medicine of the University of Navarra and in 2009 as Full Professor of Cardiovascular Medicine of the same institution. At present, he is the Director of a division of about 50 clinicians and scientists focused on cardiovascular translational research in the Centre for Applied Medical Research, and Chief of Molecular Cardiology at the University Clinic.

Dr Díez's main research interest is focused on the mechanisms of myocardial remodeling involved in hypertensive heart disease and heart failure. In addition, his work is also aimed to identify circulating biomarkers of myocardial remodeling potentially useful in the cardiac assessment of hypertensive patients. Dr. Díez's work has contributed to reveal the non-hemodynamic actions of losartan involved in its organ-protective effects in arterial hypertension. His interest extends also to the molecular basis of oxidative stress that made patients with arterial hypertension prone to develop end-organ damage and atherosclerosis.

Dr Díez is author of 290 scientific papers in leading international journals as well as more than 65 chapters in international books. He is currently a member of the Editorial Board of several journals including Hypertension, Journal of the American Society of Hypertension, Cardiovascular Research, Journal of Molecular and Clinical Pathology, Journal of Heart Disease, The Open Heart Failure Journal, High Blood Pressure & Cardiovascular Prevention, World Journal of Cardiology, and Therapeutic Advances in Cardiovascular Disease. He is also a member of various national and international clinical and scientific societies.

Recently, Dr Díez has served as councillor of the European Society of Clinical Investigation, and he is currently member of the Scientific Committees of four European Union Research Programs, and the Spanish Network for Cardiovascular Research. He is also the past President of the National Commission for Cardiovascular Diseases of the Spanish Ministry of Science and Innovation, and the current President Comission for Extramural Research Evaluation of the National Centre for Cardiovascular Research.

Dr. Díez has been recipient of several awards from international (i.e., European Society of Hypertension) and national (i.e., Spanish Society of Hypertension) scientific societies during the last years.


Arantxa González Miqueo, PhD
PUPH, Université Paris 7

Avd. Pío XII, 55 | E-31008

Tel : +34 948 194 700
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.  


Arantxa González Miqueo finalized her degree in Biochemistry in 1999 (1st National Award from the Ministry of Science and Education, Spain). She obtained her PhD in the University of Navarra in 2003, where she studied the involvement of myocardial apoptosis in the development of heart failure related to hypertensive heart disease under the supervision of Prof. Díez and Dr. Fortuño. She completed her postdoctoral training with Professors Piero Anversa and Annarosa Leri at the New York Medical College (New York, USA) and the Brigham and Women's Hospital (Boston, USA) analysing the role of resident cardiac stem cells in myocardial regeneration. In 2005 she was granted the Norman R. Alpert Award from the European Society on Cardiology and the American Heart Association.

Currently she works as staff scientist in the Division of Cardiovascular Sciences and she is Associate Professor of the School of Medicine (University of Navarra). Additionally, she is a researcher from the Ramón y Cajal Program (2010) from the Ministry of Science and Innovation (Spain) and obtained the certification as researcher of the i3 Program (2010) from the Ministry of Science and Innovation (Spain) and the Government of Navarra (Spain).

She has participated in over 60 papers published in different high impact scientific journals within the cardiovascular field. She has been involved in several competitive research National projects and in different European projects within FP6 and FP7.

Her studies are focused in the analysis of the mechanisms involved in myocardial remodelling, namely of the extracellular matrix, which plays a major role in the evolution of heart failure, as well as in the search for non-invasive circulating biomarkers of remodelling.




Kenneth McDonald, MD
Clinical Professor of Medicine
Consultant Cardiologist

St. Vincent's University Hospital
University College Dublin
Dublin 4

@: This email address is being protected from spambots. You need JavaScript enabled to view it.  


Professor Ken McDonald is the founder and Medical Director of the Heart Failure Unit at St Vincent's University Hospital, Dublin, and is presently the National Clinical Lead for Heart Failure in Ireland.

He is also the Principle Investigator of the Chronic Cardiovascular Disease Management Group and has published in excess of 100 peer reviewed articles. In addition to the clinical services provided to over 4000 patients with or at-risk of heart failure, Professor Ken McDonald has an active research programme that aims to unlock the diagnostic and therapeutic potential of a number of markers of fibrosis and inflammation in left ventricular dysfunction and heart failure.

The Unit also has a unique prospective programme evaluating biomarker risk stratification and long term follow up of patients with Stage A/B heart failure.


Chris Watson, PhD
PUPH, Université Paris 7

UCD Conway Institute,
School of Medicine & Medical Science,
University College Dublin
Dublin 4

@: This email address is being protected from spambots. You need JavaScript enabled to view it.


Dr. Chris Watson, Senior Scientist for the Chronic Cardiovascular Disease Research Group, is based in the Conway Institute, University College Dublin (UCD). He is also the Translational Research Coordinator for the Heartbeat Trust, Dublin.

Dr. Watson joined UCD in 2006 as a Newman Scholar and since then he has focused his research on the cardiovascular system and the impact that cardiovascular risk factors such as diabetes, obesity, and hypertension have on cardiac fibrosis, heart failure, and diabetic cardiomyopathy. He is actively involved in cardio-proteomic biomarker discovery programmes, pre-heart failure diagnostic and prognostic research, and generating novel therapeutic avenues for the treatment and prevention of diastolic dysfunction and heart failure.

Additional research interests include studying the epigenetic mechanisms that contribute to a fibrotic phenotype and targeting these maladaptive responses as novel therapeutic approaches.



Stephane Heymans
Professor of Cardiomyopathies
Head of the Centre for Heart Failure Research

@: This email address is being protected from spambots. You need JavaScript enabled to view it.

Stephane Heymans is Professor of Cardiomyopathies and Head of the Centre for Heart Failure Research, Department of Cardiology, Maastricht University. He obtained his Medical Degree from the KULeuven (Belgium) in 1995 and went on to get a PhD in Medical Sciences in 2000, studying the role of proteinases in acute myocardial infarction. In 2003, He joined the Cardiology Department University Hospital of Maastricht (The Netherlands) as an academic medical specialist and in 2006 he took over the Multidisciplinary Cardiomyopathy Program (Genetics, Immunology, Microbiology and Pathology departments).

In 2008 he established his independent research laboratory at Cardiovascular Research Institute Maastricht. His research interests focus on the molecular mechanisms of heart failure, looking at the interplay between inflammatory cells, fibroblasts and cardiomyocytes. Particular focus is on the role of non-structural matrix proteins, matrix turnover and non-coding RNAs.

He is chair of the Strategic Board of the Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Professor of “Inflammation and Matrix Biology in Cardiomyopathies” at the University of Leuven and he is a board member of the ESC Heart Failure Association, ESC Working Group of Myocardial Function, ESC Heart Failure Association Committee on Diastolic Heart Failure and ESC Heart Failure Association Committee on Translational Research.



Anna Papageorgiou
Senior scientist

Anna Papageorgiou is a senior scientist at the Cardiology Department, Maastricht University. She obtained her undergraduate degree in Pharmacology from University College London in 1999. She went on to complete a Masters Degree in Immunology from Imperial College, London (2000) and a PhD Degree in the medical sciences from the Katholieke Universiteit Leuven, Belgium (2007). After a post-doctoral position at University College London she joined the group of Professor Stephane Heymans in April 2009. Her research investigates the contribution of matricellular proteins to heart disease, with a special interest in inflammation-related processes.



Thomas Thum
Professor, MD, internist, cardiologist Director of the Institute for Molecular and Translational Therapeutics Strategies (IMTTS)

Hannover Medical School
IFB, Molecular and Translational Therapeutic Strategies
OE 8886
Carl-Neuberg-Str. 1
D-30625 Hannover

Phone : +49 511 532 5272
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.  


Prof. Thomas Thum is full professor and Director of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School.

Thomas Thum studied Medicine at the Hannover Medical School from 1994-2001. In 2008 he received a PhD from the Imperial College in London and finished his Internal and Cardiology Training in 2009/2010. From 2004-2009 he was a physician and scientist at the Julius-Maximilians University in Würzburg, germany. 2009 he became 
He pioneered the therapeutic use of microRNAs in cardiovascular diseases and currently develops both microRNA-based diagnostic and therapeutic strategies to improve cardiovascular diseases especially heart failure.



Sandor Batkai




Mariann Pavone-Gyöngyösi
Asc. Prof. Dr. MD PhD,
internist, cardiologist

Medical University of Vienna,
Internal Medicine II, Cardiology
Wahringer Gurtel 18-20
A-1090 Vienna, Austria

Tel: +43-1-40400-4614
Fax: +43-1-40400 -4216

@ : This email address is being protected from spambots. You need JavaScript enabled to view it.  

This email address is being protected from spambots. You need JavaScript enabled to view it.



 GreenPharma S.A.S (GP)


Quoc-Tuan DO - PhD
Chemoinformatic Manager

Greenpharma S.A.S.
3, allée du Titane
45072 Orléans Cedex 2

Phone: +
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.


Quoc-Tuan obtained his Master in Chemistry and his diploma of “ingénieur chimiste” at l’Ecole National Supérieure de Chimie de Mulhouse (France) in 1996. Then, he got his PhD in chemoinformatics at the Institut de Chimie Organique et Analytique (France). He started his career in the biophysics department of HMR at Strasbourg, in protein structure elucidation by NMR, where he familiarised with NMR & molecular modelling methodologies.

In 1997, he joined Tripos as a support scientist to complete his expertise in molecular modelling and acquired unique expertise in cutting edge molecular modelling tools and a large overview of pharmaceutical research problems and needs. By 2001, he joined Greenpharma to develop internal knowledge database system and Selnergy, a Greenpharma proprietary tool. QT is also the contact person for international collaborations.


 Firalis S.A.S. (FIR)


Prof. Hüseyin FIRAT, MD, PhD
CEO & President

Firalis S.A.S.

35 rue du Fort
68330 Huningue

Phone : +33 (0) 389 911 321
GSM : +33 (0) 631 261 605
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.  


He is a pediatrician and practiced as an associate professor in Paris University hospitals. After his PhD of Immunology at Pasteur Institute, he was accredited as research director, responsible of the Immunology Laboratory at Généthon.

In 2002, he joined then the Biomarker Department of Novartis Pharma, where he headed global omics data analysis sections worldwide, served as senior Biomarker Expert in International Project Teams and was member of Novartis Pharma Innovation Team, Basel. His research activities generated several patented discoveries, based on which three biotech companies have been created. In 2007, he has been accredited as University Professor in France and founded Firalis SAS. He is the CEO and CSO of the company since then, in coordination with several business and scientific advisors, both external and in-house.


Eric Schordan
Molecular Diagnostic Head at Firalis SAS

Firalis SAS
35 rue du Fort
68330 Huningue

Tel: +33 (0) 389 911 320
Mob +33 (0) 663 788 055
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.  


Eric Schordan is Head of Molecular Diagnostics at Firalise SAS since 2013. PhD in molecular and cellular biology in 2005 (University Louis Pasteur, Strasbourg). Laureate of an IEF Marie-Currie fellow (2006-2008). Senior postdoctorant (2009-2013).




Isbaal Ramos, PhD
Project Manager

Parque tecnológico de Bizkaia. Edificio 502-1º. 48160

Tel: +34 944005355
Fax: +34 946579925
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.  


Isbaal Ramos finalized his degree in Biology at the University of the Basque Country, Spain in 1999. After a two years working as predoctoral student in Animal Physiology, he moved to the Biophyisics Unit of CSIC, Spain where he got his PhD in 2006, for his studies in histone chaperones. Then, he moved to the Laboratory of cellular and Developmental biology at NIDDK (NIH) in USA for a postdoctoral position working on gene regulation.

In 2009 he returned to the Biophysics Unit in Spain to work as researcher. In 2011 he joined Innoprot as Project Manager and since then, he has managed Innoprot tasks in 8 international projects



Clarisa Salado, PhD
Managing Director

Parque tecnológico de Bizkaia. Edificio 502-1º. 48160
Spain Tel: +34 944005355 Fax: +34 946579925
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.  


Clarisa Salado graduated in Biochemistry at the National University of Tucuman Argentina, in 1992 and got her PhD in Biochemistry in the University of the Basque Country Spain, in 1998. After it she joined Inbiomed Fundation first as postdoc researcher and then as Director of the Cancer Chemoprevention Unit. In 2002 she moved to Dominion Pharmakine SL where she started as Analytical Biochemsitry lab chief. Later on, she worked as Director of the Biotecnology division and worked in Bussines development department as well.

In 2008, she founded Innoprot SL with 3 more partners and since then she is the Managing director of the company. She holds more than 15 years of experience in the fields of inflammation, hepatic fibrosis associated with cancer and pharmacology. Innoprot ( is a biotechnology company with extensive R&D component, located in Spain, spin-off from the University of the Basque Country. Innoprot is a provider of in vitro systems for drug discovery & development. The company is fully dedicated to custom screening services for biotech and pharma partners and offers customized assay development, high throughput screening (HTS), high content analysis (HCA) and hit-to-lead optimization services.

Innoprot personal staff combines experience in the field of drug discovery technologies with a broad expertise as pharmaceutical services providers. In addition, our company is a global supplier for human and animal cells from normal cell systems with over 90 different cell types and recombinant cell lines for toxicology and screening. Many of our cell types can only be obtained from Innoprot and are not available from any other provider.



Natalia López Andrés
Cardiovascular Translational Research

Cardiovascular Translational Research
Navarrabiomed-Fundación Miguel Servet
Centro de investigación Biomédica
Complejo hospitalario de Navarra
C/Irunlarrea 3 31008 Pamplona (Navarra)

@ : This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr Natalia López-Andrés obtained her degree in Biology at the University of Navarra in 2001 and her PhD in the Area of Cardiovascular Sciences at the Centre for Applied Medical Research (CIMA, Pamplona, Spain) in 2006. Her thesis work focused on the study of the effects of cardiotrophin-1 on adult cardiomyocytes and the involvement of this pathway in hypertensive heart disease in rats. She is experienced in Molecular and Cellular Biology and she has published four articles describing her PhD work. Then, she was fortunate to move to the UMRS_1116 (Nancy, France) and she took advantage of her experience in the area of cardiac fibrosis and extends her research to the large arteries. She continued working on cardiotrophin-1 and on other new pathways, such as galectin-3, and their effects on the cardiovascular and renal system. Moreover, she focused on Aldosterone, as one of the key molecules involved in heart failure development and progression.

She has published seven papers describing her 4-year postdoctoral research (J Hypertens, Am J Physiol Heart Circ Physiol, Eur J Heart Fail, PLoS one, Hypertension (2), ATVB). In 2013, she moved to Pamplona to lead the Cardiovascular Translational Research group in Navarrabiomed (Miguel Servet Foundation), and she has just published her first paper. Above and beyond her excellent publication record, her work has been acclaimed by several academic societies, since she has gathered an impressive number of awards relative to her scientific presentations in major international meetings. She is member of the Heart Failure Association, of the myocardial function working group and of the Galectin-3 working group (sponsored by BG Medicine). Her communication skills led her to be invited as guest speaker in a number of institutions and scientific meetings.


Enrique Santamaria Martinez
Proteomics Unit

Proteomics Unit
Navarrabiomed-Fundación Miguel Servet
Centro de investigación Biomédica
Complejo hospitalario de Navarra
C/Irunlarrea 3
31008 Pamplona (Navarra)

@ : This email address is being protected from spambots. You need JavaScript enabled to view it.  


Dr Enrique Santamaria obtained his degree in Biochemistry at the University of Navarra in 2001 and his PhD in the Area of Biochemical Hepatology at the Centre for Applied Medical Research (CIMA, Pamplona, Spain) in 2005. His thesis work focused on the identification of potential biomarkers of non-alcoholic steatohepatitis and hepatocellular carcinoma in murine models and human samples using proteomic technologies. He is experienced in proteome analysis and he was author of four articles and co-inventor of three patents during his PhD period.

From 2006 to 2009, he was involved in a FP6 project where he applied high-throughput genomic and proteomic strategies to study the interactions between the HSV-1 proteome and the normal and cancer cells to improve the HSV-1 based oncolytic vectors in terms of potency and safety. As a result of this work, he published 4 papers describing his postdoctoral research (Liver Int, Journal of Proteomics, and Molecular and Cellular Proteomics (2)). As a complement of his scientific training, he completed a Master in Business Management of SME in 2008.

In 2011, she moved to Navarrabiomed (Miguel Servet Foundation) to establish the Proteomics Unit with the aim of providing proteomic technology services to the scientific community as well as biotech companies. Due to his scientific background, he is also leading the Clinical Neuroproteomics group in Navarrabiomed. Nowadays, the Proteomics Unit collaborates in the Human Proteome Project, analysing and characterizing the chromosome 16 protein-coding genes in the human nervous system.